Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

TREATRUSH · Fighting blindness of Usher syndrome: diagnosis, pathogenesis and retinal treatment (TreatRetUsher)

FP7Status: CLOSED1 February 201031 January 2014EU funding €6,000,000

Usher syndrome (USH) is the most frequent hereditary cause of deafness associated to blindness. It is a rare disease, affecting 1 in every 10.000 individuals, with an autosomal recessive monogenic inheritance. Deafness is congenital while the retinitis pigmentosa is not detected before the age of 8 to 10. These patients suffer from a dreadful disability as their two major senses are impaired. Important scientific advances have been achieved, mostly by auditory scientists: 9 causative genes have been identified. The hearing impairment pathogenesis has been elucidated, ie, an early developmental defect of auditory sensory cells. Our project gathering scientists and physicians from both the auditory and visual fields aims : -to halt the no longer acceptable underdiagnosis of this syndrome. Because, children affected with Usher type I, the most severe form, are usually diagnosed as severely or profoundly deaf only, parents may choose visual/sign language whereas these children would have taken full advantage from an early cochlear implantation. -To make these patients benefit from gene replacement therapy in the retina that recently showed tremendous results. We propose : 1/ To develop new clinical and molecular tools and guidelines for an early diagnosis thereafter broadly disseminated. 2/To clarify the retinal pathogenesis of Usher syndrome (type I and II) by an unpreceding effort to generate animal and tissue models that will be characterised in depth by multidisciplinary investigations including innovative methods. Mouse, frog, pig in vivo models and cultured retinal explants will be used, as well as human retinal cultures. This will also provide the necessary tests to evaluate phenotype rescuing. 3/To prevent and treat the retinal defect by associated adenovirus (AAV) gene therapy. This includes optimisation of the gene transfer and selection of patients to lead to a clinical trial carried out for one or more Usher genes (USH1B, 1C, 1G & USH2D)

Consortium · 13 organisations

coordinator

UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

FR · €1,599,999

participant

FONDATION DE COOPERATION SCIENTIFIQUE VOIR ET ENTENDRE

FR · €408,000

participant

Novartis Forschungsstiftung

CH

participant

FONDAZIONE TELETHON ETS

IT · €502,000

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €459,999

participant

JOHANNES GUTENBERG-UNIVERSITAT MAINZ

DE · €197,000

participant

FAUN - STIFTUNG NURNBERG

DE · €20,000

participant

FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH FONDATION

CH · €502,000

participant

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CORP

US · €341,827

participant

MASSACHUSETTS EYE AND EAR INFIRMARY

US · €135,695

participant

AMSTERDAM MOLECULAR THERAPEUTICS (AMT) BV

NL · €502,000

participant

EBERHARD KARLS UNIVERSITAET TUEBINGEN

DE · €829,480

participant

MEDICAL RESEARCH COUNCIL

UK · €502,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.